Repros Low-Testosterone Therapy NDA May Be Delayed Until 4Q 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is preparing two head-to-head studies against approved testosterone replacement therapies to try to demonstrate Androxal’s superiority, even as apparent data fraud at a study site may alter the final analysis of a pivotal Phase III study.
You may also be interested in...
Repros' Hypogonadism Treatment Enclomiphene Heads To FDA Panel
Efficacy and safety data for drug, formerly known as Androxal, will be vetted by FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee Nov. 3.
Repros’ Androxal Primed For NDA Submission, But Outcomes Study Looms
The testosterone drugmaker is confident that Androxal can gain approval and is on track to submit a filing with FDA this year, but a cardiovascular outcomes study is still on the table.
Repros’ Androxal Primed For NDA Submission, But Outcomes Study Looms
The testosterone drugmaker is confident that Androxal can gain approval and is on track to submit a filing with FDA this year, but talk of a cardiovascular outcomes study is still on the table.